Abstract:335 Background: Immune checkpoint inhibitors (ICIs) plus chemotherapy has become the standard first-line regimen for advanced GC/GEJC, but the efficacy still needs to be improved. Fruquintinib is an oral, highly selective VEGFR 1/2/3 inhibitor that has synergistic antitumor effects when combined with ICIs/chemotherapy. Additionally, the phase III study (NCT03223376) of fruquintinib combined with paclitaxel in second-line GC/GEJC has achieved positive topline result. Therefore, this study was aimed to evaluate the efficacy and safety of fruquintinib combined with SOX and toripalimab as a first-line therapy in GC/GEJC. Methods: In this phase Ib/II, open-label trial (NCT05024812), patients (pts) aged 18-75 years who were HER2-negative with no previous anti-tumor therapy were enrolled. The Ib phase employed a 3+3 dose escalation design, pts were treated with fruquintinib 3mg/d, po, d1-14 (dose level; DL1), 4mg/d (DL2), or 5mg/d (DL3) in combination with fixed dose of toripalimab (240mg, iv, d1), oxaliplatin (130 mg/m 2 , iv, d1) and S-1 (40-60mg based on BSA, po, d1-14) every 3 weeks. The primary objective of phase Ib was to determine the DLT in first treatment cycle defining the PR2D. Additional 64 pts were enrolled in the phase II dose expansion stage using RP2D. Primary endpoint of phase II was PFS per RECIST 1.1. Secondary endpoints included ORR, DCR, OS, DOR and safety. Results: At data cut-off (August 31, 2023), 17 pts (9 in phase Ib; 8 in phase II) with median age 65 years old had been enrolled. 59% were male, 100% had ECOG PS 1 and 35% had liver metastasis. 10/17 (59%) pts were PD-L1 CPS ≥1. No DLTs were observed at all three dose levels. Fruquintinib 5mg/d was defined as the RP2D. Of the 16 pts evaluable for tumor response, 9 pts achieved PR, 7 pts achieved SD. The ORR was 56.3% (9/16), the DCR was 100% (16/16). Pts with PD-L1 CPS <1 were more likely to achieve better responses (4PR in 6 pts, ORR-66.7%). After a median follow-up of 5.4 months, the median PFS was 9.3 (95% CI: 4.76–NA) months and OS result was not mature. Median DOR was not reached and two responders were estimated to have a response duration ≥8.0 months. Majority of TRAEs were grade 1-2, including neutrophil count decreased (64.3%), white blood cell decreased, hypoproteinemia and platelet count decreased (all were 42.9%). Grade 3 TRAEs included neutrophil count decreased (11.8%), platelet count decreased, impaired liver function, rash, pruritus and mucositis (5.9%, one patient for each). There were no treatment related deaths in the trial. Conclusions: Fruquintinib combined with SOX and toripalimab was well tolerated, with encouraging antitumor activity as first-line treatment for advanced metastatic GC/GEJC, especially in pts with CPS <1. The trial is still recruiting, more data including the potential predictive response biomarkers would be further analyzed and reported. Clinical trial information: NCT05024812 .

Fruquintinib combined with sintilimab plus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma: A single-arm phase II study.

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non‒Small-Cell Lung Cancer.

Fruquintinib with Gefitinib As First-Line Therapy in Patients Carrying EGFR Mutations with Advanced Non-Small Cell Lung Cancer: a Single-Arm, Phase II Study

637P A Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Combined with Tislelizumab and Hepatic Artery Infusion Chemotherapy (HAIC) for Advanced Colorectal Cancer Liver Metastases (CRLM)

OA11.03 A Randomized, Multi-Center, Double-Blind Phase II Study of Fruquintinib in Patients with Advanced Non-Small Cell Lung Cancer

Fruquintinib plus sintilimab in patients with either treatment-naive or previously first line treated metastatic clear-cell renal cell carcinoma (ccRCC): Results from a multicenter, single-arm phase 2 study.

JCES 01.12 A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations

Phase Ib/II Trial of Hepatic Arterial Infusion Chemotherapy in Combination with Fruquintinib for Refractory Unresectable Colorectal Cancer Liver Metastases.

A Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Combined with Tislelizumab and Hepatic Artery Infusion Chemotherapy (HAIC) for Advanced Colorectal Cancer Liver Metastases: an Updated Analysis of Survival.

Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: A multicenter, single-arm phase 2 trial.

1494P Fruquintinib Combined with Sintilimab and Chemotherapy As the First-Line Treatment in Advanced Naive EGFR- and ALK-negative Non-Squamous Non-Small Cell Lung Cancer(nsq-Nsclc): Updated Results of a Phase II Trial

Fruquintinib combined with sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): A phase II, single-arm, prospective study.

Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study

Phase II study of fruquintinib as second or further-line therapy for patients with advanced biliary tract cancer.

Efficacy and Safety of Fruquintinib Plus Investigator's Choice of Chemotherapy As Second-Line Therapy in Metastatic Colorectal Cancer: Updated Results of a Multicenter, Single-Arm, Phase 2 Trial.

A phase Ib/II study of fruquintinib in combination with SOX and toripalimab as first-line treatment for advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).

The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study

TACE combined with the intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: A prospective, single-arm, phase II study.

A phase 2 study of fruquintinib in combination with S-1 for second-line treatment of esophageal squamous cell carcinoma after first-line immunotherapy failure.

A phase I/IIa study of cetuximab combined with fruquintinib in the previously treated RAS/BRAF wild-type metastatic colorectal cancer: Results of the CEFRU study.

Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study